


Call for Expressions of Interest

Bioinformaticians/computational biologists

The newly established **Single-Cell Analysis Unit** in the <u>Kollias</u> <u>lab</u> at the Biomedical Sciences Research Center 'Alexander Fleming' is looking for highly motivated bioinformaticians or computational biologists to join its team.

Team members will have the opportunity to implement state-of-the-art analysis methodologies for **multi-omic single-cell Next Generation Sequencing** experiments (10x Genomics Technologies: e.g. single-cell RNA-seq, ATAC-seq, SNV, spatial transcriptomics, etc) and get involved in research projects that aim to decipher complex biological processes related to single-cell pathology.

Applicants should have basic skills in programming (R or Python) and statistics. Experience in the analysis of Next Generation Sequencing data will be considered a significant advantage.



The candidates should hold a BSc degree in Computer Science or related fields (e.g. Engineering, Applied Math, Physics, etc) or/and an MSc degree in Bioinformatics or related fields (e.g. Computational Biology, Biostatistics, etc). Additionally, applicants should have good communication skills to help provide support both to members of the Single-Cell Analysis Unit team as well as internal and external users.

Expressions of interest should be sent to Dr. Dimitris Konstantopoulos, Head of the new Unit, at konstantopoulos@fleming.gr. Candidates should include a curriculum vitae, a short letter outlining the candidate's interests and expertise (max. 1 page), and also the contact information of at least two referees.

Deadline for submissions of expressions of interest: 23 April 2021

BSRC Fleming is a top-ranked Greek non-profit research organization focusing on scientific and technological excellence, training and innovation in biomedical sciences. The Center was established in 1998, and operates under the supervision of the General Secretariat for Research and Technology (GSRT) of the Hellenic Ministry of Education. Competitive funding each year amounts to 75-85% of the total budget of the Center, an achievement that underlies Fleming's strategic prioritization of research and innovation. The Center has gained international recognition for its pioneering research towards understanding the molecular and cellular basis of human diseases such as autoimmune diseases, cancer, neurodegenerative disorders, osteoporosis, pulmonary fibrosis and others, and the development of new approaches for their diagnosis and treatment. Fleming's strength and international visibility lies on its focus and success in developing and characterizing animal models that mimic human disease and the Center has consequently invested heavily on related infrastructures.